U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 1691 - 1700 of 21518 results

Status:
Investigational
Source:
INN:turosteride
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Turosteride [FCE 26073] is a selective 5α-reductase inhibitor being developed by Pharmacia Corporation. Turosteride inhibits human and rat prostatic 5 alpha-reductases with IC50 values of 55 and 53 nM, respectively. It was in phase II clinical trials in Italy for the treatment of benign prostatic hyperplasia.
Status:
Investigational
Source:
INN:floxacrine
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

FLOXACRINE, a dihydroacridinedione derivative, is an antimalarial agent. It showed high potency against blood-induced infection of drug-sensitive and drug-resistant lines of Plasmodium berghei in animal models.
Status:
Investigational
Source:
INN:fluperamide [INN]
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Fluperamide was developed as an antiperistaltic agent for the treatment of diarrhea. However, information about the current use of the drug is not available.
Status:
Investigational
Source:
NCT00543816: Phase 3 Interventional Terminated Diabetes Mellitus, Type 2
(2003)
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


MK-0767 is a potent hypoglycaemic insulin sensitizer being evaluated by Kyorin with potential as an antidiabetic agent. MK-0767 acts as a dual agonist of the peroxisome proliferator-activated receptors alpha and gamma, induced high-affinity interactions of PPARα and PPARγ with the transcriptional coactivator CBP in vitro. In ob/ob mice, MK-0767 normalized hyperglycemia and hyperinsulinemia with equal or greater potency and efficacy than pioglitazone. Treatment of hamsters with MK-0767 produced substantial reductions in blood cholesterol and triglycerides. In dogs, MK-0767 reduced serum cholesterol levels with a potency more than 10-fold greater than simvastatin. The efficacies of MK-0767 and simvastatin were additive when given together.
Status:
Investigational
Source:
INN:flutonidine
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Flutonidine, an alpha2-adrenergic receptor agonist was studied as an antihypertensive drug. However, information about the current use of this drug is not available.
Status:
Investigational
Source:
INN:tetriprofen
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Tetriprofen is a hydratropic acid derivative patented by Swiss chemical company CIBA Ltd as an antinociceptive and anti-inflammatory agent.
Status:
Investigational
Source:
INN:ketocainol
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

KETOCAINOL is an antiarrhythmic agent, anaesthetic.
Status:
Investigational
Source:
INN:formebolone
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Formebolone is an orally active anabolic-androgenic steroid that is included in the list of prohibited substances by the World Anti-Doping Agency. Formebolone was used in Italy and Spain for infants with malnutrition.
Status:
Investigational
Source:
INN:sunagrel
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Sunagrel is a phenylethanolamine derivative patented by Maggioni Farmaceutici S.p.A. as platelet aggregation inhibitor and antilipidaemic agent.
Status:
Investigational
Source:
INN:sabeluzole [INN]
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)

Sabeluzole (previously known as R 58 735) was developed for the treatment of Alzheimer's disease. It reached phase II clinical trials in Canada and Belgium before its development was discontinued. This drug possibly acts as N-methyl-D-aspartate (NMDA) receptor antagonist. In addition, the effect of sabeluzole on sleep, breathing and daytime symptoms was investigated in 13 patients with obstructive sleep apnea. Besides, no beneficial effect of sabeluzole was shown on peripheral nerve function in patients at an early stage of diabetic polyneuropathy.

Showing 1691 - 1700 of 21518 results